MARK HALL: Open Payments
NPI 1578833026 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 29 payments from 10 companies in 2025. Trend: 2023 $551 · 2024 $427 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $148 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $112 |
| Averitas Pharma Inc. | 5 | $87 |
| Collegium Pharmaceutical, Inc. | 3 | $67 |
| Boston Scientific Corporation | 1 | $32 |
| Valinor Pharma, LLC | 2 | $29 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $28 |
| Globus Medical, Inc. | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Bioventus LLC | 1 | $17 |
Products named: BOTOX, RELISTOR, QUTENZA, Belbuca, Intracept, MOVANTIK, JOURNAVX, Senza.
Industry payments across OK — which companies pay providers there.
